

SEPTEMBER 2024

RESQUNIT

Health, life sciences investments

A strategic approach

STOCKHOLM, SWEDEN
WWW.RESQUNIT.COM

Introduction


RESQUNIT AB (publ) is a company listed on Nasdaq First North Growth Market in Stockholm Sweden and has acted as a holding company since listing in 2021, primarily financed and supported its subsidiary RESQUNIT AS in Norway. The company is adding to its holdings a specialized holding branch with a clear focus on acquiring significant positions in health and life sciences companies listed on Nasdaq Sweden and the London Stock Exchange.

Unlike traditional investment funds, RESQUNIT utilizes its own equity and capital, providing the company with the flexibility and strategic freedom to make long-term investments that are not constrained by the typical pressures from external investors. Drawing inspiration from other proven successes of leading venture capital firms in life sciences, RESQUNIT aims to foster innovation and drive growth in companies that are at the forefront of medical and technological advancements.

This document provides a detailed overview of RESQUNIT's investment strategy, market focus, competitive advantages, and future outlook. It is designed to offer potential investors and partners an in-depth understanding of how RESQUNIT operates and why it is uniquely positioned to create significant value in the health and life sciences sector.



Helge Trettö Olsen
Resqunit AB CEO



Mission and Vision

➔ Mission

RESQUNIT's mission is to strategically invest in and support innovative health and life sciences companies that are poised to drive significant advances in healthcare and improve global health outcomes. We are committed to fostering growth in companies that have the potential to deliver breakthrough solutions to unmet medical needs.

➔ Core Values


- Innovation: We are dedicated to investing in companies that are at the cutting edge of medical and technological advancements, driving the future of healthcare.
- Strategic Growth: Our investments are focused on sustainable, long-term growth, ensuring that we maximize value for both our portfolio companies and our stakeholders.
- Value Creation: We are committed to generating substantial returns through strategic investments and active involvement in the growth and development of our portfolio companies.

Company overview

➔ Holding division

RESQUNIT is a holding company that strategically acquires and manages equity positions in health and life sciences companies across key global financial markets. Our primary focus is on companies listed on Nasdaq Sweden and the London Stock Exchange. We invest in companies that demonstrate strong growth potential, groundbreaking innovation, and the ability to make a significant impact on global healthcare. Additionally, we actively seek exceptional teams that can add value across our portfolio, fostering synergies and driving collective success among our target companies.

By leveraging our own equity and capital, we are able to take a long-term view on our investments, supporting companies through various stages of their growth without the constraints typically associated with traditional investment funds. Our approach is inspired by the successes of other industry investment funds but tailored to suit our unique structure and goals.



Investment Strategies

Target Markets

RESQUNIT focuses on acquiring significant positions in health and life sciences companies listed on Nasdaq Sweden and the London Stock Exchange. Our investments span key sectors within these markets, including:

- Pharmaceuticals: Firms focused on innovative drug development, particularly those targeting lifestyle diseases, chronic conditions, and areas with high unmet medical need.
- Medical Devices: Companies that are creating advanced medical devices and diagnostics that improve patient outcomes and enhance the efficiency of healthcare delivery.
- Digital Health: Emerging companies at the intersection of healthcare and technology, including those involved in telemedicine, AI-driven diagnostics, and patient data management.

Investment Approach

- Active Ownership: RESQUNIT acquires significant equity positions in our target companies, enabling us to take an active role in shaping their strategic direction. Our involvement goes beyond financial investment; we work closely with management teams to ensure that these companies have the resources and guidance they need to achieve their full potential.
 - Long-Term Perspective: Unlike typical investment funds, RESQUNIT is not bound by the need to return capital to external investors within a set timeframe. This allows us to hold our positions until the full value of our investments is realized, supporting companies through the various phases of their growth.
 - Scalability Focus: We prioritize companies with scalable technologies and business models that can address large, unmet medical needs. Our goal is to invest in firms that not only have innovative solutions but also the potential to become leaders in their respective fields.
- 

MARKET OPPORTUNITIES

➔ Health and Life Sciences Sector Growth

The global health and life sciences market is experiencing unprecedented growth, driven by several key factors:

- Aging Populations: As global populations age, the demand for healthcare services, chronic disease management, and innovative treatments is increasing rapidly.
- Chronic Diseases: The rising prevalence of chronic diseases such as diabetes, cancer, and cardiovascular conditions is driving the need for new therapies and new approaches.
- Technological Advancements: The integration of technology into healthcare is creating new opportunities for innovation, from AI-driven diagnostics to personalized medicine.

➔ Innovation Pipeline

By investing in companies with robust pipelines of novel therapies and technologies, RESQUNIT is well-positioned to capitalize on future healthcare trends. Our focus on innovation ensures that our portfolio companies are at the forefront of medical advancements, with the potential to bring transformative products to market.



Comparative advantage

RESQUNIT leverages strategic insights using our own equity and capital, allowing for greater flexibility and alignment with long-term company growth.

Unique Positioning

RESQUNIT's approach is distinct in several key ways:

- **Capital Flexibility:** Using our own capital gives us the ability to make investment decisions based on the long-term potential of a company, rather than short-term investor demands. This allows us to hold positions until the full value of our investments is realized, without the pressure of having to exit at predetermined timelines.
 - **Active Involvement:** Our significant equity positions enable us to take an active role in the strategic direction of our portfolio companies. This involvement goes beyond typical board-level engagement; we work closely with management to ensure that they have the resources, guidance, and strategic insight needed to succeed.
 - **Proven Expertise:** Our team brings deep experience in identifying and nurturing companies that deliver breakthrough innovations and achieve commercial success. We combine financial acumen with a strong understanding of the scientific and regulatory landscapes, positioning us to make informed investment decisions
- 

Portfolio highlights

RESQUNIT has already demonstrated its capability and strategic foresight by securing substantial ownership stakes in four innovative companies (pending Nasdaq approval). These companies, each with their own unique focus, are set to play a significant role in the health and life sciences sector.

➔ **Twiiik AB (publ) (Now Metabolic Nordic AB (publ))**

Twiiik AB, originally an innovation company based in Malmö, specialized in developing digital fitness experiences for both individuals and companies. With offices in Stockholm, the company helped health industry players offer engaging digital services to their customers. RESQUNIT, as part of an investment group, initiated a strategic name change to Metabolic. This transition included integrating the DR.VITOS concept, creating immediate opportunities for short-term revenue from its unique position to make weight reduction medications, such as Ozempic, more accessible to European markets.

➔ **Hemcheck Sweden AB (publ) (Now Bio Vitos Pharma AB (publ))**

Hemcheck produced and marketed a patented CE-marked concept for point-of-care detection of hemolysis, a common reason why blood samples cannot be analyzed accurately. The investment group, including RESQUNIT, led the transformation of Hemcheck into Bio Vitos Pharma, focusing on the development, production, and commercialization of iron succinate for treating iron deficiency. The new entity also plans to introduce affordable home testing kits for measuring iron levels and holds IP rights to commercialize Omega 3 supplements, with LOI agreements already in place with pharmacies abroad.

Portfolio highlights

➔ QuiaPEG Pharmaceuticals Holding AB (publ) (Now Quia Pharma AB (publ))

QuiaPEG was known for its patented drug delivery platform, Uni-Qleaver®. RESQUNIT's investment group facilitated the company's rebranding to Quia Pharma and expanded its global sales to include Omega 3, astaxin, and collagen through Amazon. Additionally, the company is exploring the development of a long-acting patch containing PEG-liraglutide for treating obesity, which could provide a more convenient alternative to current daily injection methods. This solution is slated to be licensed and sold by Net Zero Infrastructure PLC (NZI), a London Exchange-listed company in which RESQUNIT also has an ownership stake.

➔ EXIT STRATEGY

RESQUNIT maintains a strategic approach to exiting its investments. A key element of this strategy is to divest 30% of its holdings once the share price of an investment has doubled within 12 months. This approach allows RESQUNIT to realize gains while retaining a significant stake in high-performing companies for continued growth.

Management Team

➔ CEO, Board Member



Helge Trettø Olsen

Education and background

Mr. Olsen has extensive experience in entrepreneurship, business development, and C-suite roles as he has executed two successful exits of companies either founded or co-founded by Mr. Olsen. His first exit was with the company ETRIP AS (2007 – 2014), founded in 2007, where he held a majority of 70% equity at the time it was acquired by private equity owned ABAX AS in 2014. Three years later, in 2017, he sold the self-developed patented invention Shield, a sensor which detects scratches and dents on vehicles. Prior to his ventures, Mr. Olsen served as the regional manager of Konica Minolta Business Solutions Norway AS (1998 – 2004) in Stavanger, Hordaland, and Haugesund, Møre og Romsdal. He has a background in IT including a degree as Microsoft Certified Professional.

Other current assignments

CEO and Chairman of the Board Trettø Olsen Invest As

Board Member of Podbike AS

Board Member of Firemesh AS

Board Member of Jufoo AS

Holdings in the Company

Mr Trettø Olsen is the Company's largest shareholder

Management Team

➔ CFO



Henning Johannessen

Education and background

Mr. Henning Johannessen graduated as a state-authorized auditor from the Norwegian School of Economics (NHH) in 2002. He is also a certified accountant. Johannessen has long experience working as both auditor, accountant and CFO. He worked 11 years as an auditor with Deloitte (1997–2008), serving clients of different sizes and a large variety of industries. Then he served 9 years as CFO with Viking Fotball AS (2008–2017) in a period that was economically challenging for the company, and he participated in two capital increases. During this period, he was also acting CEO at two instances. From 2017 to 2022 he has been working as an accountant. The first four years with BDO and recently for a small local accounting firm Inforegn AS where he is part owner.

➔ CMO



Per Jan Waagen

Education and background

Per is the CMO, co-owner, and co-founder of the Company. Waagens background is in computer and electronics and as a business developer. Throughout his career, he has partaken and co-founded several ventures and held C-suite marketing- and technical roles. Together with Resqunit's current CEO, Helge Trettø Olsen, he co-founded ETRIP AS (2007 – 2014) and served as the company's CTO before it was acquired by ABAX AS in 2014. Furthermore, he has a background in electronics and computing, specializing in hardware and industrial computer systems for harsh environments in the oil and gas industry. Waagen has 20 years of experience in software and business development, including 3D Bolig AS (2006 – 2021) a concept for online 3D-visualization within the proptech sector, and the e-commerce platform Shop123 (2003 – present), which he co-founded in 2006 and 2003, respectively.

Board of Directors

➔ Chairman



Alf Reime

Education and background

Alf Reime has extensive board experience over the last 30 years through positions such as Chairman of Espenes AS (2002 – present), Vest Bemanning AS (2012 – 2014), and Jærens ærverdige forening for Uisge Beatha's fremme (1996 – present).

Mr. Reime has primarily worked in the ERP space and held positions such as global account executive at Lawson Software (1993 – 2008), senior account executive at Infor (2008 – 2016) and managing director at SE Labels (1991 – 1993). Additionally, he has 10 years of experience from Oilfield Services companies, both offshore and onshore, including running logistics and IT for Baker Atlas' (1977 – 1985) EMEA operations.

➔ MEMBER



Thomas Nordheim

Education and background

Thomas Nordheim has significant experience in mergers and acquisitions (M&A), due diligence, and business valuations, accumulated over nearly two decades in various roles within the financial and corporate sectors. Since November 2014, he has been the owner of Enex AS, where he specializes in M&A, due diligence, and business valuation services. Prior to this, Mr. Nordheim held the position of Senior Manager at EY (2011–2014), focusing on M&A, following his earlier role as Manager at EY (2009–2011) where he was involved in M&A, due diligence, and valuation projects. His M&A experience also includes his time at First Securities in 2008.

Before transitioning to M&A and advisory roles, Mr. Nordheim served as a corporate advisor at SpareBank 1 SR-Bank (2006–2007) and contributed to the academic community as a lecturer in corporate financial analysis at Handelshøyskolen BI in 2006. His career began in the field of auditing with EY (2004–2006), following earlier roles at Aker Offshore Partner as a database operator and web designer in 1998. Mr. Nordheim holds a degree from the Norwegian School of Economics (NHH).

Board of Directors

➔ Member



Jesper Carlsöö

Education and background

Jesper will bring extensive experience in project development, formerly serving as the Head of Project Development and Leasing at Logistea AB. With a distinguished career spanning over 20 years, including key roles at the executive management level in publicly listed real estate companies, with a focus on logistics and industry. Jesper has consistently demonstrated his expertise and leadership.

➔ MEMBER



Richard Wall

Education and background

Richard currently serves as Chairman of the Board in Nasdaq-listed Bio Vitos Pharma AB, a company specializing in hemolysis detection services. With a solid background in military cadet training and business administration, Richard has held significant management roles in the service industry, overseeing over 500 employees. His extensive experience includes leadership positions such as Sales Manager at Ahlsell and CEO of Wallmega AB, a company he founded. Additionally, Richard holds board memberships in Wall Group AB, Wiam Holding AB, and Målerimästarna Stockholm AB. Richard is independent in relation to the Company and the Group management. Independent in relation to the Company's major shareholders.

➔ MEMBER



Helge Trettö Olsen

Investment committee

Comprised of seasoned professionals, the committee is responsible for identifying investment opportunities, conducting thorough due diligence, and guiding portfolio companies to success.



Öjje Holt

Öjje Holt is a seasoned executive with a remarkable track record in launching and scaling innovative tech-driven businesses. As a co-founder and Chief Revenue Officer **of Acast**, he played a pivotal role in the global launch of Acast+, the first-ever podcast premium service. Under his leadership, Acast received multiple accolades, including being named one of Wired's Top 100 Innovative Companies in Europe and winning the Red Herring Top 100 Europe Entertainment and Media Award in 2016. His contributions helped the company go public in 2021.

At Spotify, as Managing Director Nordics, Holt was instrumental in driving the platform's growth across the Nordic region, including the successful launches in Denmark, the Baltics, and Iceland. His efforts earned Spotify the "Best Sales Organization 2011" award at the Stockholm Media Awards.

Prior to Spotify, Holt served as Head of iTunes Retail International **at Apple**, where he spearheaded the expansion of the iTunes gift card program across Europe, achieving over 100% revenue growth quarter over quarter and significantly expanding the retail footprint.

Holt's earlier career **at Microsoft** as Country Manager for the Entertainment and Devices Division in Sweden saw him leading the Xbox 360 to secure the #1 market share in EMEA during 2007-08, and his team received the Polaris Award from Bill Gates for best team management in EMEA. His tenure at Microsoft was marked by multiple recognitions, including the Circle of Excellence Award presented by Steve Ballmer.



Helge Trettö Olsen

As presented above

Investment committee

**Nicklas Wall**

Född 1993. Nicklas Wall har en master inom industriell ekonomi och har genomgått Leadership Academy vid University of Oxford. Med över 7 års erfarenhet som managementkonsult har Nicklas Wall drivit kunders strategiska initiativ, varit ansvarig för globala transformationsprogram samt förvaltat inlåningsverksamheter.

**Richard Wall**

As presented above

**Jesper Carlsöö**

As presented above

**Martin Larsson**

Martin Larsen is a seasoned C-level executive, entrepreneur, and co-founder with over 20 years of experience in the Swedish banking and financial sectors. He has held leadership roles such as CEO & Co-Head of Corporate Finance at Pepins (2022 – present) and Founder & CEO of Greenshoe Capital (2019 – present). Mr. Larsen co-founded Qvantea Capital, where he served as Chairman & COO (2019 – 2021), and played a pivotal role in preparing Northern CapSek Ventures for its IPO (2018 – 2019). He also led a management buy-out at Glase FinTech AB (2017 – 2019) and established Mangold Securities at Mangold Fondkommission AB (2008 – 2017).

Investment committee



Vidar Wendel-Hansen

Vidar Wendel-Hansen has over 20 years of experience in the life science industry, with a strong background in molecular diagnostics, preclinical and clinical drug development, and medical affairs. He has held significant roles at companies such as **Pharmacia Biotech, Gilead Sciences, and Novartis**, as well as at start-up biotech firms specializing in areas like metabolism, infectious diseases, vaccines, oncology, and neuroscience. Additionally, he served as a clinical investigator for infectious disease drugs and vaccines at the Swedish Medical Products Agency.

Mr. Wendel-Hansen is a seasoned project manager and leader, co-author of 11 publications, and co-inventor of **4 patents**. He currently holds board positions at **VWH & Company Aktiebolag** and **Castello di Vaglio Serra AB**. He is a board member of **QuiaPEG** since 2023.



Hans Marcus Bosson

Marcus holds a degree in Business Administration from the Stockholm School of Economics and has also studied law at Stockholm University. He has approximately 20 years of experience in both the venture capital industry, where he served as the CEO of **Ryda Bruk AB**, and in the pharmaceutical development industry, as an entrepreneur and senior executive. Prior to this, Marcus worked for the **Swedish-American Chamber of Commerce** in New York for four years. He is a co-founder of a pharmaceutical development company that has collectively raised over 800 million SEK in venture capital.

Marcus has also been involved in the planning and execution of two clinical trials and has played a key role in driving and negotiating out-licensing agreements in several companies. He co-founded **QuiaPEG Pharmaceuticals AB** in 2012.

Financial Strategy

➔ Capital Allocation

RESQUNIT strategically deploys its own capital into companies with strong growth potential, allowing for agile investment decisions and the ability to support companies through multiple stages of their development. Our approach to capital allocation is designed to maximize returns while ensuring that our portfolio companies have the resources they need to succeed.

➔ Revenue and profitability goals

Our focus on long-term investments is aimed at generating sustainable, high returns. We target companies that can achieve significant value inflections through clinical milestones, regulatory approvals, and commercial success. Profits generated from successful investments are reinvested to expand our portfolio and increase our influence within the sector.

➔ Reinvestment strategy

RESQUNIT's profits are reinvested to further strengthen our portfolio and support the growth of new and existing investments. This reinvestment strategy ensures that we continue to build value over time, both for RESQUNIT and for the companies in which we invest.

Risk Management

Risk Mitigation Strategies

RESQUNIT employs a comprehensive risk management strategy to protect our investments and maximize returns. Key components of this strategy include

- **Diversification:** We diversify our investments across multiple sectors and geographic markets to reduce exposure to any single market or regulatory environment. This approach helps mitigate risks associated with market volatility and regulatory changes.
- **Thorough Due Diligence:** Before making any investment, RESQUNIT conducts rigorous due diligence, including scientific, clinical, regulatory, and commercial assessments. This ensures that we invest in companies with strong fundamentals and the potential for significant growth.
- **Active Portfolio Management:** RESQUNIT closely monitors its portfolio companies, providing strategic support and resources as needed. Our active involvement allows us to address challenges and capitalize on opportunities in real time.

Future Outlook

Growth Projections

RESQUNIT is committed to continuing its growth trajectory by identifying and investing in new opportunities within the health and life sciences sector. Over the next 3–5 years, we plan to:

- **Expand Our Portfolio:** We will continue to seek out high-potential companies in emerging areas.
- **Increase Global Reach:** Through our portfolio companies, we plan to expand our geographical footprint, particularly in markets with high growth potential such as Europe and North America.

Innovation and Expansion

RESQUNIT is focused on expanding its portfolio through innovative investments in emerging technologies and markets. Our goal is to increase our influence in the global health and life sciences sector by strategically acquiring stakes in companies that are at the forefront of medical innovation.

Disclaimer

This newsletter may contain certain forward-looking statements that reflect Resqunit's views concerning future events and financial and operational performance. Words such as "intends", "assesses", "expects", "can", "plans", "estimates" or other expressions that relate to indications or predictions concerning future development or trends and that are not based on historical facts constitute forward-looking statements. Forward-looking statements are, by nature, associated with known as well as unknown risks and uncertainties, given their dependence on future events and circumstances. Forward-looking statements are no guarantee of future results or trends, and the actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements in this newsletter apply only as of the date of this publication. Resqunit does not give any undertaking that the Company will disclose any updates or revisions of forward-looking statements due to new information, future events or other such matters above and beyond what is required according to applicable laws.

Contact



www.resqunit.com



post@resqunit.com



+47 901 68 908